Therapy Areas
Celyad Oncology to sell cell therapy manufacturing capability to Cellistic
20 September 2022 -

Cellistic, the cell therapy development and manufacturing business of biotechnology company Ncardia BV, is to acquire Good Manufacturing Practice (GMP) grade cell therapy manufacturing capability from Celyad Oncology (Euronext:CYAD) (Nasdaq:CYAD), the two companies announced on Tuesday.

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.

Under the terms of an asset purchase agreement between Celyad Oncology and Cellistic, Cellistic has agreed to acquire Celyad Oncology's manufacturing business unit in Mont-Saint-Guibert, Belgium, for a total consideration of EUR6m. A team of more than 30 manufacturing, quality and related personnel from Celyad Oncology, all with cell therapy manufacturing and immune-oncology experience, will join Cellistic as part of this transaction.

Cellistic said it will invest substantial capital into the newly acquired 11,000 sq ft facility, which will be optimised for its iPSC-based allogeneic cell therapy platforms and processes.

Subject to a number of customary conditions, the transaction is is anticipated to close in the fourth quarter of 2022.